Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of adjunctive aripiprazole in patients with major depressive disorder

Next Previous
X
Search
Trial Profile

A study of adjunctive aripiprazole in patients with major depressive disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary) ; Antidepressants
  • Indications Depression; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 24 Mar 2014 A post hoc analysis of pooled data from 3 phase 3 studies, was published in Journal of Affective Disorders.
    • 06 Jun 2013 Based on results of this study, and CN138-139 and CN138-165, aripiprazole has received approval from Health Canada as adjunctive treatment of major depressive disorder, according to a Bristol-Myers Squibb media release.
    • 24 Aug 2010 Results of a pooled analysis [trial profiles 700004743 and 700011903] on suicidal ideation resulting from aripiprazole therapy published in the Journal of Clinical Psychiatry.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top